Mealey's (September 15, 2021, 10:02 AM EDT) -- SILVER SPRING, Md. — The Food and Drug Administration on Sept. 2 announced that it is requiring revisions to the black box warnings for Xeljanz, Olumiant and Rinvoq due to the increased risk of heart attack or stroke, cancer, blood clots and death....